Pfizer and Moderna vaccine, high efficacy 7 months after second dose

The effectiveness of mRna anti-Covid vaccines – Pfizer and Moderna – remains high over time, 7 months after the second dose. It falls, however, in front of the Delta variant. These are some of the data released by the Higher Institute of Health (Iss), based on the fourth report by the Iss-Ministry of Health Working Group ‘Covid-19 vaccine surveillance’. Read also EFFECTIVENESS At least in the general population for which, “7 months after the second dose” of vaccine, there is no significant reduction in efficacy in terms of protection from infection (symptomatic or asymptomatic), which remains at 89%. against hospitalization and death the protection remains high (96% and 99%) 6 months after the second dose “. This was reported by the Higher Institute of Health (Iss), on the basis of the fourth report – by the Iss-Ministry of Health Working Group ‘Covid-19 vaccine surveillance’ – on the joint analysis of data from the integrated Covid-19 surveillance and of the National Vaccines Registry. The data of more than 29 million people who received at least one dose of the vaccine at mRna, followed up to 29 August 2021, reports the ISS. The efficacy – he specifies – was evaluated by comparing the incidence of infections (symptomatic and asymptomatic), hospitalizations and deaths at different time intervals after the second dose with that observed in the 14 days after the first dose, considered as a control period. “In the first months of vaccination”, therefore, “the protection of the risk of infection in the general population remains high, while a reduction in efficacy over time has been observed for immunocompromised and frail people. 7 months after vaccination there is no reduction in efficacy of Covid-19 mRna vaccines in the general population, while a slight decrease in protection from infection (symptomatic or asymptomatic) is observed in some specific groups “. The experts highlight that “the data are consistent with those obtained from the comparison with the non-vaccinated, published weekly in the extended report of the ISS. It is essential to continue this type of updates and monitoring in future months”, they recommend. of Pfizer and Moderna vaccines falls ahead of the Delta variant. “Comparing the data between January and June 2021, the period in which the Alpha” variant of the coronavirus predominated, “with those between July and August, the Delta” variant “prevalence, a reduction in the effectiveness” of mRna anti-Covid vaccines emerges. “against infection from 84.8% to 67.1%. The efficacy against hospitalizations remains high (91.7% against 88.7%)”. “The apparent reduction in the effectiveness of vaccines in preventing infection – the experts specify – could be due to the time elapsed from vaccination and / or to a decreased effectiveness against the Delta variant. Possible behavioral changes, following the relaxation of other preventive measures (use of masks, physical distancing) “. FRAGILE AND OVER 80 PATIENTS Unlike healthy people, a reduction in the effectiveness of the vaccine is observed in immunocompromised people, in those with comorbidities, in the over 80 and in the guests of Rsa. In particular, “in immunocompromised people a reduction of the protective effect against infection is observed starting from 28 days after the second dose”. But “the estimate, in this case – specifies the ISS – presents a high variability due in part to the small number of subjects included in this group, but also connected to the diversity of the pathologies present in this category”. comorbidity, there is a reduction in protection from infection, from a 75% risk reduction after 28 days from the second dose to 52% after approximately 7 months “. Finally, “the effectiveness against infection in people over 80 and in residents of the RSA slightly decreases, while remaining above 80%”.